{
    "id": 60080,
    "name": "Her2-receptor negative breast cancer",
    "source": "DOID",
    "definition": "A breast cancer that is characterized by the absence of Her2 receptors. [url:https\\://www.ncbi.nlm.nih.gov/pubmed/25682076]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:0060080",
    "evidence": [
        {
            "id": 1004,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a meta-analysis of 844 ERBB2 (HER2)-negative breast cancer patients, Nexavar (sorafenib) increased progression-free survival time, but not overall survival or objective response rate (PMID: 24940450).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 716,
                    "pubMedId": 24940450,
                    "title": "Sorafenib-based therapy in HER2-negative advanced breast cancer: Results from a retrospective pooled analysis of randomized controlled trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24940450"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1065,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Cyramze (ramucirumab) in combination with Taxotere (docetaxel) did not improve clinical outcomes in ERBB2 (HER2)-negative breast cancer patients (PMID: 25185099).",
            "molecularProfile": {
                "id": 1184,
                "profileName": "ERBB2 negative"
            },
            "therapy": {
                "id": 1423,
                "therapyName": "Docetaxel + Ramucirumab",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 665,
                    "pubMedId": 25185099,
                    "title": "Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25185099"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2522,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PALOMA-2) that supported FDA approval, the addition of Ibrance (palbociclib) to treatment with Femara (letrozole) prolonged progression-free survival (24.8 mo vs 14.5 mo) in patients with ERBB2 (HER2)-negative-ER-positive breast cancer compared to Femara (letrozole) plus placebo (PMID: 27959613, PMID: 26100274; NCT01740427).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 2922,
                "therapyName": "Letrozole + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3246,
                    "pubMedId": 26100274,
                    "title": "Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26100274"
                },
                {
                    "id": 10754,
                    "pubMedId": 27959613,
                    "title": "Palbociclib and Letrozole in Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27959613"
                },
                {
                    "id": 15541,
                    "pubMedId": null,
                    "title": "Ibrance (palbociclib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207103"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2659,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, treatment with the combination of Avastin (bevacizumab) and Taxotere (docetaxel), Adrucil (fluorouracil), Ellence (epirubicin), and Cytoxan (cyclophosphamide) (D-FEC) resulted in improved efficacy over D-FEC alone in ERBB2 (HER2)-negative breast cancer patients, with pathological complete response in breast and lymph nodes in 22% (87/388) of patients (PMID: 25975632).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2988,
                "therapyName": "Bevacizumab + Cyclophosphamide + Docetaxel + Epirubicin + Fluorouracil",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3374,
                    "pubMedId": 25975632,
                    "title": "Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25975632"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2660,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, strongly ESR1 (ER)-positive patients with ERBB2 (HER2)-negative breast cancer had a decreased response to the combination of Avastin (bevacizumab), docetaxel, fluorouracil, epirubicin, and cyclophosphamide compared to ESR1-negative and weakly positive patients, with complete response (CR) in 6% (14/232) compared to an overall CR of 22% (87/388) (PMID: 25975632).",
            "molecularProfile": {
                "id": 27929,
                "profileName": "ERBB2 neg ESR1 pos"
            },
            "therapy": {
                "id": 2988,
                "therapyName": "Bevacizumab + Cyclophosphamide + Docetaxel + Epirubicin + Fluorouracil",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3374,
                    "pubMedId": 25975632,
                    "title": "Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25975632"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6657,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (BOLERO-2) that supported FDA approval, the combination of Afinitor (everolimus) and Aromasin (exemestane) resulted in an improved median progression-free survival (7.8 vs 3.2 months) compared to Aromasin (exemestane) and placebo in patients with ERBB2 (HER2)-negative, hormone receptor-positive breast cancer whose disease recurred or progressed during or after nonsteroidal aromatase inhibitor therapy (PMID: 24158787; NCT00863655).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 1966,
                "therapyName": "Everolimus + Exemestane",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10766,
                    "pubMedId": 24158787,
                    "title": "Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24158787"
                },
                {
                    "id": 15547,
                    "pubMedId": null,
                    "title": "Afinitor (everolimus) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022334"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12383,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, the combination of Afinitor (everolimus) and Aromasin (exemestane) improved progression-free survival compared to Aromasin (exemestane) and placebo in patients with ERBB2 (HER2)-negative, hormone-receptor-positive breast cancer regardless of their PIK3CA mutational status (PMID: 28183140).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 1966,
                "therapyName": "Everolimus + Exemestane",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10362,
                    "pubMedId": 28183140,
                    "title": "Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28183140"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6540,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Seribantumab (MM-12) and Aromasin (exemestane) combination treatment resulted in a 74% decrease in risk of progression (HR 0.26) and a a 59% decrease in risk of death (HR 0.436) compared to exemestane alone in ERBB2-negative, hormone receptor positive breast cancer patients (AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer, May 2016, Abstract # A14).",
            "molecularProfile": {
                "id": 1184,
                "profileName": "ERBB2 negative"
            },
            "therapy": {
                "id": 4141,
                "therapyName": "Exemestane + Seribantumab",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5690,
                    "pubMedId": null,
                    "title": "Identification of heregulin expression as a driver of a difficult-to-treat cancer phenotype and development of a prospective companion diagnostic for the heregulin-ErbB3 targeting drug seribantumab",
                    "url": "http://files.shareholder.com/downloads/AMDA-IWDM2/2127694404x0x892308/7BACAE03-69E0-423A-A4D5-8A19EFED7AE1/MM-121_AACR_Precision_Medicine_Poster_11May2016_FINAL.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6873,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Veliparib (ABT-888) in combination with Platinol (cisplatin) and Navelbine (vinorelbine) resulted in a complete response in 4% (2/48), partial response in 31% (15/48), and stable disease in 44% (31/48) of patients with Erbb2 (Her2) negative breast cancer (PMID: 26801247).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4286,
                "therapyName": "Cisplatin + Veliparib + Vinorelbine",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5936,
                    "pubMedId": 26801247,
                    "title": "Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26801247"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6874,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Veliparib (ABT-888), in combination with Platinol (cisplatin) and Navelbine (vinorelbine), resulted in a greater complete response (7%, 1/14), partial response (50%, 7/14), and 6-month progression free survival rate (71%, 10/14) in Erbb2 (Her2) negative breast cancer patients harboring germline BRCA1 or BRCA2 mutations compared to BRCA wild-type patients (PMID: 26801247).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 4286,
                "therapyName": "Cisplatin + Veliparib + Vinorelbine",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5936,
                    "pubMedId": 26801247,
                    "title": "Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26801247"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6875,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Veliparib (ABT-888) in combination with Platinol (cisplatin) and Navelbine (vinorelbine) resulted in a greater complete response (7%, 1/14), partial response (50%, 7/14), and 6-month progression free survival rate (71%, 10/14) in Erbb2 (Her2) negative breast cancer patients harboring germline BRCA1 or BRCA2 mutations compared to BRCA wild-type patients (PMID: 26801247).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 4286,
                "therapyName": "Cisplatin + Veliparib + Vinorelbine",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5936,
                    "pubMedId": 26801247,
                    "title": "Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26801247"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7139,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with LY3039478 resulted in partial response in one patient with ER-positive, PR-positive, ERBB2 (HER2)-negative breast cancer (J Clin Oncol 33, 2015 (suppl; abstr 2533)).",
            "molecularProfile": {
                "id": 24496,
                "profileName": "ERBB2 neg ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 2958,
                "therapyName": "LY3039478",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5879,
                    "pubMedId": null,
                    "title": "First-in-human study of LY3039478, a Notch signaling inhibitor in advanced or metastatic cancer",
                    "url": "http://meetinglibrary.asco.org/content/144588-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7167,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, the combination of Vantictumab (OMP-18R5) and Taxol (paclitaxel) was well-tolerated and demonstrated preliminary efficacy in patients with metastatic HER2-negative breast cancer (J Clin Oncol 34, 2016 (suppl; abstr 2516)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4398,
                "therapyName": "Paclitaxel + Vantictumab",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6128,
                    "pubMedId": null,
                    "title": "Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with Paclitaxel (P) in patients (pts) with 1st- to 3rd-line metastatic HER2-negative breast cancer (BC).",
                    "url": "http://meetinglibrary.asco.org/content/166396-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8861,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, circulating tumor cells (CTC) from patients with ERBB2 (HER2)-negative breast cancer were demonstrated to contain both ERBB2 (HER2)-positive and ERBB2 (HER2)-negative subpopulations, and the combination of LY411575 and Taxol (paclitaxel) resulted in increased tumor growth inhibition in CTC-derived xenograft models compared to either agent alone (PMID: 27556950).",
            "molecularProfile": {
                "id": 26477,
                "profileName": "ERBB2 neg ERBB2 pos"
            },
            "therapy": {
                "id": 4841,
                "therapyName": "LY411575 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6775,
                    "pubMedId": 27556950,
                    "title": "HER2 expression identifies dynamic functional states within circulating breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27556950"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8862,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, circulating tumor cells (CTC) from patients with ERBB2 (HER2)-negative breast cancer were demonstrated to contain both ERBB2 (HER2)-positive and ERBB2 (HER2)-negative subpopulations, and the combination of RO4929097 and Taxol (paclitaxel) resulted in increased tumor growth inhibition in CTC-derived xenograft models compared to either agent alone (PMID: 27556950).",
            "molecularProfile": {
                "id": 26477,
                "profileName": "ERBB2 neg ERBB2 pos"
            },
            "therapy": {
                "id": 4840,
                "therapyName": "Paclitaxel + RO4929097",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6775,
                    "pubMedId": 27556950,
                    "title": "HER2 expression identifies dynamic functional states within circulating breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27556950"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14539,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (MONALEESA-7) that supported FDA approval, Kisqali (ribociclib) in combination with a non-steroidal aromatase inhibitor (Femara (letrozole) or Arimidex (anastrozole)) resulted in significantly improved median progression-free survival (23.8 vs 13.0 months, HR=0.55, p<0.0001) compared to placebo in premenopausal women with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer (PMID: 29804902; NCT02278120).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 1568,
                "therapyName": "Letrozole + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11737,
                    "pubMedId": 29804902,
                    "title": "Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29804902"
                },
                {
                    "id": 15548,
                    "pubMedId": null,
                    "title": "Kisqali (ribociclib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8957,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (MONALEESA-2) that supported FDA approval, Kisqali (ribociclib) plus Femara (letrozole) as first-line therapy resulted in an 18 month progression-free survival rate of 63.0% compared to 42.2% with placebo plus Femara (letrozole), and an overall response rate of 52.7%, compared to 31.7% with placebo in postmenopausal women with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer (PMID: 27717303; NCT01958021).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 1568,
                "therapyName": "Letrozole + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6802,
                    "pubMedId": 27717303,
                    "title": "Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27717303"
                },
                {
                    "id": 15548,
                    "pubMedId": null,
                    "title": "Kisqali (ribociclib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9713,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with ERBB2 (HER2)-receptor negative breast cancer harboring AKT1 E17K demonstrated a complete metabolic response when treated with Ipatasertib (GDC-0068) (PMID: 27872130).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 747,
                "therapyName": "Ipatasertib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7487,
                    "pubMedId": 27872130,
                    "title": "A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27872130"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10434,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, combination of Navelbine (vinorelbine) and Nexavar (sorafenib) resulted in a response rate of 30% (8/27), median progression free survival of 5.7 months, and a clinical benefit rate (absence of disease progression at 6 months) of 48% (13/27) in patients with ERBB2 (HER2)-negative metastatic breast cancer (PMID: 27992451).",
            "molecularProfile": {
                "id": 1184,
                "profileName": "ERBB2 negative"
            },
            "therapy": {
                "id": 2357,
                "therapyName": "Sorafenib + Vinorelbine",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8447,
                    "pubMedId": 27992451,
                    "title": "Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27992451"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11131,
            "approvalStatus": "FDA approved - Has Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (OlympiAD) that supported FDA approval, Lynparza (olaparib) treatment resulted in significantly improved median progression-free survival (7.0 vs 4.2 months, HR=0.58, p<0.001) and higher response rate (59.9% vs 28.8%) compared to standard chemotherapy in ERBB2 (HER2)-negative breast cancer patients harboring a deleterious or suspected deleterious germline BRCA mutation (PMID: 28578601; NCT02000622).",
            "molecularProfile": {
                "id": 1282,
                "profileName": "BRCA1 inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10614,
                    "pubMedId": 28578601,
                    "title": "Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28578601"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15467,
                    "pubMedId": null,
                    "title": "Lynparza (olaparib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18818,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Lynparza (olaparib) is included in guidelines as systemic treatment for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-negative breast cancer harboring BRCA1/2 germline mutations (NCCN.org).",
            "molecularProfile": {
                "id": 1282,
                "profileName": "BRCA1 inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11132,
            "approvalStatus": "FDA approved - Has Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (OlympiAD) that supported FDA approval, Lynparza (olaparib) treatment resulted in significantly improved median progression-free survival (7.0 vs 4.2 months, HR=0.58, p<0.001) and higher response rate (59.9% vs 28.8%) compared to standard chemotherapy in ERBB2 (HER2)-negative breast cancer patients harboring a deleterious or suspected deleterious germline BRCA mutation (PMID: 28578601; NCT02000622).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10614,
                    "pubMedId": 28578601,
                    "title": "Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28578601"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15467,
                    "pubMedId": null,
                    "title": "Lynparza (olaparib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18819,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Lynparza (olaparib) is included in guidelines as systemic treatment for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-negative breast cancer harboring BRCA1/2 germline mutations (NCCN.org).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 21140,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an ERBB2 (HER2)-negative/ESR1 (ER)-positive breast cancer cell line demonstrated sensitivity to treatment with Abemaciclib (LY2835219) in xenograft models, resulting in decreased tumor volume (PMID: 27217383).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6356,
                    "pubMedId": 27217383,
                    "title": "Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27217383"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11835,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (MONARCH 1) that supported FDA approval, Verzenio (abemaciclib) treatment resulted in an objective response rate of 19.7% (26/132), a clinical benefit rate of 42.4% (56/132), median progression-free survival of 6.0 months, and median overall survival of 17.7 months in patients with refractory hormone receptor positive, Erbb2 (Her2) negative metastatic breast cancer (PMID: 28533223; NCT02102490).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9866,
                    "pubMedId": 28533223,
                    "title": "MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28533223"
                },
                {
                    "id": 15550,
                    "pubMedId": null,
                    "title": "Verzenio (abemaciclib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11836,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (MONARCH 1) that supported FDA approval, Verzenio (abemaciclib) treatment resulted in an objective response rate of 19.7% (26/132), a clinical benefit rate of 42.4% (56/132), median progression-free survival of 6.0 months, and median overall survival of 17.7 months in patients with refractory hormone receptor positive, Erbb2 (Her2) negative metastatic breast cancer (PMID: 28533223; NCT02102490).",
            "molecularProfile": {
                "id": 1856,
                "profileName": "PGR positive"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9866,
                    "pubMedId": 28533223,
                    "title": "MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28533223"
                },
                {
                    "id": 15550,
                    "pubMedId": null,
                    "title": "Verzenio (abemaciclib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12063,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, addition of AZD5363 to Taxol (paclitaxel) did not improve progression free survival compared to placebo (10.9 vs 8.4 months) in patients with Esr1-positive, Erbb2 (Her2)-negative breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 241PD; NCT01625286).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2192,
                "therapyName": "Capivasertib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9995,
                    "pubMedId": null,
                    "title": "BEECH: A randomised Phase 2 study assessing the efficacy of AKT inhibitor AZD5363 combined with paclitaxel in patients with ER+ve advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population",
                    "url": "http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12064,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the addition of AZD5363 to Taxol (paclitaxel) therapy did not improve progression-free survival compared to placebo (10.9 vs 10.8 months) in patients with PIK3CA-mutant, Esr1-positive, Erbb2 (Her2)-negative breast cancer (PMID: 30860570; NCT01625286).",
            "molecularProfile": {
                "id": 429,
                "profileName": "PIK3CA mutant"
            },
            "therapy": {
                "id": 2192,
                "therapyName": "Capivasertib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14619,
                    "pubMedId": 30860570,
                    "title": "BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30860570"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12092,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (MONARCH 2) that supported FDA approval, the combination treatment of Verzenio (abemaciclib) and Faslodex (fulvestrant) resulted in a greater median progression-free survival compared to Faslodex (fulvestrant) plus placebo (16.4 mo vs 9.3 mo, HR=0.553, p<0.0001) and improved objective response rate (48.1% vs 21.3 %) in hormone receptor-positive, ERBB2 (HER2) receptor-negative breast cancer patients (PMID: 28580882; NCT02107703).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 5859,
                "therapyName": "Abemaciclib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9173,
                    "pubMedId": 28580882,
                    "title": "MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28580882"
                },
                {
                    "id": 10030,
                    "pubMedId": null,
                    "title": "MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2017.73.7585"
                },
                {
                    "id": 15550,
                    "pubMedId": null,
                    "title": "Verzenio (abemaciclib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12093,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (MONARCH 2) that supported FDA approval, the combination treatment of Verzenio (abemaciclib) and Faslodex (fulvestrant) resulted in a greater median progression-free survival compared to Faslodex (fulvestrant) plus placebo (16.4 mo vs 9.3 mo, HR=0.553, p<0.0001) and improved objective response rate (48.1% vs 21.3 %) in hormone receptor-positive, ERBB2 (HER2) receptor-negative breast cancer patients (PMID: 28580882; NCT02107703).",
            "molecularProfile": {
                "id": 1856,
                "profileName": "PGR positive"
            },
            "therapy": {
                "id": 5859,
                "therapyName": "Abemaciclib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9173,
                    "pubMedId": 28580882,
                    "title": "MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28580882"
                },
                {
                    "id": 15550,
                    "pubMedId": null,
                    "title": "Verzenio (abemaciclib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12202,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, the combination therapy of Taxol (paclitaxel) and Reparixin in patients with metastatic ERBB2 (HER2)-receptor negative breast cancer resulted in a 30% (8/27) response rate and a durable response greater than 12 months in two patients (PMID: 28539464; NCT02001974).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6353,
                "therapyName": "Paclitaxel + Reparixin",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10154,
                    "pubMedId": 28539464,
                    "title": "Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2-Negative Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28539464"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12381,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, addition of MK2206 to Arimidex (anastrozole) treatment did not further induce apoptosis and resulted in no pathologic complete response (0/13) in estrogen receptor-positive, Erbb2 (Her2)-negative breast cancer patients harboring PIK3CA mutations (PMID: 28874413; NCT01776008).",
            "molecularProfile": {
                "id": 28721,
                "profileName": "ERBB2 neg ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 4188,
                "therapyName": "Anastrozole + MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10361,
                    "pubMedId": 28874413,
                    "title": "A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28874413"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12384,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PMMB-187 inhibited Stat3 activation and growth of Erbb2 (Her2)-negative breast cancer cell lines in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 29066190).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 6485,
                "therapyName": "PMMB-187",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10364,
                    "pubMedId": 29066190,
                    "title": "Identification of new shikonin derivatives as STAT3 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29066190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12555,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with ERBB2 (HER2)-receptor negative breast cancer harboring FGFR1 amplification demonstrated antitumor activity when treated with Votrient (pazopanib), including a near complete loss of brain lesions and improved function of the liver (PMID: 29223982).",
            "molecularProfile": {
                "id": 812,
                "profileName": "FGFR1 amp"
            },
            "therapy": {
                "id": 848,
                "therapyName": "Pazopanib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10422,
                    "pubMedId": 29223982,
                    "title": "Pazopanib Sensitivity in a Patient With Breast Cancer and FGFR1 Amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29223982"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14540,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (MONALEESA-7) that supported FDA approval, Kisqali (ribociclib) in combination with a non-steroidal aromatase inhibitor (Femara (letrozole) or Arimidex (anastrozole)) resulted in significantly improved median progression-free survival (23.8 vs 13.0 months, HR=0.55, p<0.0001) compared to placebo in premenopausal women with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer (PMID: 29804902; NCT02278120).",
            "molecularProfile": {
                "id": 1856,
                "profileName": "PGR positive"
            },
            "therapy": {
                "id": 1568,
                "therapyName": "Letrozole + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11737,
                    "pubMedId": 29804902,
                    "title": "Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29804902"
                },
                {
                    "id": 15548,
                    "pubMedId": null,
                    "title": "Kisqali (ribociclib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12604,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (MONALEESA-2) that supported FDA approval, Kisqari (ribociclib) plus Femara (letrozole) as first-line therapy resulted in an 18 month progression-free survival rate of 63.0% compared to 42.2% with placebo plus Femara (letrozole), and an overall response rate of 52.7%, compared to 31.7% with placebo in patients with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer (PMID: 27717303; NCT01958021).",
            "molecularProfile": {
                "id": 1856,
                "profileName": "PGR positive"
            },
            "therapy": {
                "id": 1568,
                "therapyName": "Letrozole + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6802,
                    "pubMedId": 27717303,
                    "title": "Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27717303"
                },
                {
                    "id": 15548,
                    "pubMedId": null,
                    "title": "Kisqali (ribociclib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12830,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PALOMA-3) that supported FDA approval, the combination of Faslodex (fulvestrant) with Ibrance (palbociclib) resulted in an improved progression-free survival of 9.5 months, compared to 4.6 months with Faslodex (fulvestrant) plus placebo in ERBB2 (HER2) negative, ESR1 (ER)-positive breast cancer patients (PMID: 26947331, PMID: 27407089; NCT01942135).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6771,
                    "pubMedId": 27407089,
                    "title": "FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27407089"
                },
                {
                    "id": 10765,
                    "pubMedId": 26947331,
                    "title": "Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26947331"
                },
                {
                    "id": 15541,
                    "pubMedId": null,
                    "title": "Ibrance (palbociclib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207103"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13177,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in an object response rate of 24% (6/25), a clinical benefit rate of 40% (10/25), and a median progression-free survival of 3.5 months in patients with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 1216,
                "profileName": "ERBB2 mutant"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13218,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 3.5 months in a patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) D769H (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 3128,
                "profileName": "ERBB2 D769H"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13219,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response with a progression-free survival of 3.5 months in one patient, and stable disease with a progression-free survival of 20.0 months in another patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) G778_P780dup (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 3278,
                "profileName": "ERBB2 G778_P780dup"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13220,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response with a progression-free survival of 9.0 months in a patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) L755_E757delinsS (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 29032,
                "profileName": "ERBB2 L755_E757delinsS"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13221,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in complete response in 1 patient, partial response in 1 patient, stable disease in 2 patients, and progressive disease in 4 patients with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) L755S (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13222,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 2.8 months in a patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) L841V (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 17958,
                "profileName": "ERBB2 L841V"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13223,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response with a progression-free survival of 3.6 months in a patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) L869R (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 18584,
                "profileName": "ERBB2 L869R"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13224,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in complete response with a progression-free survival of 14.6 months in one patient, and stable disease with a progression-free survival of 3.7 months in another patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) S310F (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 3284,
                "profileName": "ERBB2 S310F"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13225,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response in one patient, and progressive disease in 4 patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) V777L (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13226,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in complete response in one patient, and stable disease in 2 patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) Y772_A775dup (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 3148,
                "profileName": "ERBB2 Y772_A775dup"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13302,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in complete response in 1, partial response in 1, and stable disease in 3 of the 5 patients with Erbb2 (Her2)-receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) exon 20 insertion mutations (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 22000,
                "profileName": "ERBB2 exon 20 ins"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13826,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, RB1 K240Sfs*22 and TP53 R248W were identified in the circulating tumor DNA of a patient with estrogen receptor positive, progesterone receptor positive, and Erbb2 (Her2)-negative, invasive ductal carcinoma at the time of disease progression after 5 months of Ibrance (palbociclib) and Faslodex (fulvestrant) combination treatment (PMID: 29236940).",
            "molecularProfile": {
                "id": 29560,
                "profileName": "RB1 K240Sfs*22 TP53 R248W"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11295,
                    "pubMedId": 29236940,
                    "title": "Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29236940"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13827,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, RB1 mutations including E268*, I101fs, T738_R775del, and V654fs were identified in the circulating tumor DNA of a patient with estrogen receptor positive, progesterone receptor positive, and Erbb2 (Her2)-negative, invasive ductal carcinoma at the time of disease progression after 8 months of Ibrance (palbociclib) and Faslodex (fulvestrant) combination treatment (PMID: 29236940).",
            "molecularProfile": {
                "id": 29570,
                "profileName": "RB1 I101fs RB1 E268* RB1 V654fs RB1 T738_R775del"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11295,
                    "pubMedId": 29236940,
                    "title": "Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29236940"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13828,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, RB1 H48Y was identified in the circulating tumor DNA of a patient with estrogen receptor positive, progesterone receptor positive, and Erbb2 (Her2)-negative, invasive ductal carcinoma at the time of disease progression after 13 months of Kisqali (ribociclib) and Femara (letrozole) combination treatment (PMID: 29236940).",
            "molecularProfile": {
                "id": 29571,
                "profileName": "RB1 H483Y"
            },
            "therapy": {
                "id": 1568,
                "therapyName": "Letrozole + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11295,
                    "pubMedId": 29236940,
                    "title": "Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29236940"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13900,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Alpelisib (BYL719) treatment resulted in a disease control rate of 60.9% (14/23, 0 complete response (CR), 1 partial response (PR), 13 stable disease (SD)), and a clinical benefit rate (CR+PR+SD>24 weeks) of 17.4% (4/23) in patients with ER-positive, ERBB2 (HER2)-negative breast cancer harboring PIK3CA mutations (PMID: 29401002; NCT01219699).",
            "molecularProfile": {
                "id": 429,
                "profileName": "PIK3CA mutant"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11345,
                    "pubMedId": 29401002,
                    "title": "Phosphatidylinositol 3-Kinase \u03b1-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29401002"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13906,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Alpelisib (BYL719) treatment resulted in no clinical benefit in 4 patients with ER-positive, ERBB2 (HER2)-negative breast cancer harboring PIK3CA mutations (PMID: 29401002; NCT01219699).",
            "molecularProfile": {
                "id": 430,
                "profileName": "PIK3CA wild-type"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11345,
                    "pubMedId": 29401002,
                    "title": "Phosphatidylinositol 3-Kinase \u03b1-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29401002"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19953,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Taselisib (GDC-0032) combined with Faslodex (fulvestrant) improved objective response rate (ORR) (20.3%, 48/236 vs 9.7%, 10/103, p=0.0202) compared to placebo in patients with ER-positive, ERBB2 (HER2)-negative breast cancer harboring PIK3CA mutations, ORR was significantly improved in patients with multiple PIK3CA mutations (30.2%, 13/43 vs 8.7%, 2/23, p=0.0493), but not in patients with single PIK3CA mutations (18.1%, 35/193 vs 10.0%, 8/80, p=0.0981) (PMID: 31699932; NCT02340221).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 4567,
                "therapyName": "Fulvestrant + Taselisib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17631,
                    "pubMedId": 31699932,
                    "title": "Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K\u03b1 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699932"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14171,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (SANDPIPER) trial, Taselisib (GDC-0032) in combination with Faslodex (fulvestrant) significantly improved progression-free survival (7.4 vs 5.4 months, HR=0.70, p=0.0037) and objective response rate (28.0% vs 11.9%, p=0.0002) compared to placebo in patients with ER-positive, ERBB2 (HER2)-negative locally advanced or metastatic breast cancer harboring PIK3CA mutations (J Clin Oncol 36, 2018 (suppl; abstr LBA1006); NCT02340221).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 4567,
                "therapyName": "Fulvestrant + Taselisib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11485,
                    "pubMedId": null,
                    "title": "Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.",
                    "url": "https://meetinglibrary.asco.org/record/158535/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14537,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (MONALEESA-3) trial that supported FDA approval, Faslodex (fulvestrant) in combination with Kisqali (ribociclib) resulted in significantly improved median progression-free survival (20.5 vs 12.8 months, HR=0.593, p<0.001) compared to Faslodex (fulvestrant) plus placebo in postmenopausal women with hormone receptor-positive, Erbb2 (Her2)-negative, advanced breast cancer (PMID: 29860922; NCT02422615).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 2316,
                "therapyName": "Fulvestrant + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11736,
                    "pubMedId": 29860922,
                    "title": "Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29860922"
                },
                {
                    "id": 15548,
                    "pubMedId": null,
                    "title": "Kisqali (ribociclib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14538,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (MONALEESA-3) trial that supported FDA approval, Faslodex (fulvestrant) in combination with Kisqali (ribociclib) resulted in significantly improved median progression-free survival (20.5 vs 12.8 months, HR=0.593, p<0.001) compared to Faslodex (fulvestrant) plus placebo in postmenopausal women with hormone receptor-positive, Erbb2 (Her2)-negative, advanced breast cancer (PMID: 29860922; NCT02422615).",
            "molecularProfile": {
                "id": 1856,
                "profileName": "PGR positive"
            },
            "therapy": {
                "id": 2316,
                "therapyName": "Fulvestrant + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11736,
                    "pubMedId": 29860922,
                    "title": "Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29860922"
                },
                {
                    "id": 15548,
                    "pubMedId": null,
                    "title": "Kisqali (ribociclib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14541,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (MONALEESA-7) that supported FDA approval, Kisqali (ribociclib) in combination with a non-steroidal aromatase inhibitor (Femara (letrozole) or Arimidex (anastrozole)) resulted in significantly improved median progression-free survival (23.8 vs 13.0 months, HR=0.55, p<0.0001) compared to placebo in premenopausal women with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer (PMID: 29804902; NCT02278120).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 7166,
                "therapyName": "Anastrozole + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11737,
                    "pubMedId": 29804902,
                    "title": "Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29804902"
                },
                {
                    "id": 15548,
                    "pubMedId": null,
                    "title": "Kisqali (ribociclib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14542,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (MONALEESA-7) that supported FDA approval, Kisqali (ribociclib) in combination with a non-steroidal aromatase inhibitor (Femara (letrozole) or Arimidex (anastrozole)) resulted in significantly improved median progression-free survival (23.8 vs 13.0 months, HR=0.55, p<0.0001) compared to placebo in premenopausal women with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer (PMID: 29804902; NCT02278120).",
            "molecularProfile": {
                "id": 1856,
                "profileName": "PGR positive"
            },
            "therapy": {
                "id": 7166,
                "therapyName": "Anastrozole + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11737,
                    "pubMedId": 29804902,
                    "title": "Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29804902"
                },
                {
                    "id": 15548,
                    "pubMedId": null,
                    "title": "Kisqali (ribociclib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15060,
            "approvalStatus": "FDA approved - Has Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (EMBRACA) that supported FDA approval, Talzenna (talazoparib) treatment resulted in significantly longer median progression-free survival (8.6 vs 5.6 months, HR=0.54, p<0.001), and higher objective response rate (62.6% vs 27.2%, OR=5.0, p<0.001) compared to standard chemotherapy in patients with advanced ERBB2 (HER2)-negative breast cancer harboring known deleterious or suspected deleterious germline mutations in BRCA1 or BRCA2 (PMID: 30110579; NCT01945775).",
            "molecularProfile": {
                "id": 1282,
                "profileName": "BRCA1 inact mut"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12586,
                    "pubMedId": 30110579,
                    "title": "Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30110579"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15468,
                    "pubMedId": null,
                    "title": "Talzenna (talazoparib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18821,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Talzenna (talazoparib) is included in guidelines as systemic treatment for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-negative breast cancer harboring BRCA1/2 germline mutations (NCCN.org).",
            "molecularProfile": {
                "id": 1282,
                "profileName": "BRCA1 inact mut"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18820,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Talzenna (talazoparib) is included in guidelines as systemic treatment for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-negative breast cancer harboring BRCA1/2 germline mutations (NCCN.org).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15061,
            "approvalStatus": "FDA approved - Has Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (EMBRACA) that supported FDA approval, Talzenna (talazoparib) treatment resulted in significantly longer median progression-free survival (8.6 vs 5.6 months, HR=0.54, p<0.001), and higher objective response rate (62.6% vs 27.2%, OR=5.0, p<0.001) compared to standard chemotherapy in patients with advanced ERBB2 (HER2)-negative breast cancer harboring known deleterious or suspected deleterious germline mutations in BRCA1 or BRCA2 (PMID: 30110579; NCT01945775).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12586,
                    "pubMedId": 30110579,
                    "title": "Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30110579"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15468,
                    "pubMedId": null,
                    "title": "Talzenna (talazoparib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17066,
            "approvalStatus": "FDA approved - Has Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19566,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "The combination of Faslodex (fulvestrant) and Piqray (alpelisib) is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-negative breast cancer harboring a PIK3CA mutation (NCCN.org).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15154,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (SOLAR-1) trial, Alpelisib (BYL719) and Faslodex (fulvestrant) combination therapy significantly improved median progression-free survival (11.0 vs 5.7 months, HR=0.65, p=0.00065), and overall response rate (36% vs 16%, p=0.0002) compared to placebo in hormone receptor-positive, Erbb2 (Her2)-negative breast cancer patients harboring PIK3CA mutations (ESMO 2018 Congress, Oct 2018, Presidential Symposium 1, abstract LBA3; NCT02437318).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12748,
                    "pubMedId": null,
                    "title": "Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the Phase 3 SOLAR-1 trial",
                    "url": "https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Alpelisib-ALP-fulvestrant-FUL-for-advanced-breast-cancer-ABC-results-of-the-Phase-3-SOLAR-1-trial"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15183,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, LY3039478 treatment resulted in partial response lasted 9.5 months in a patient with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer harboring FBXW7 mutation (PMID: 30060061; NCT01695005).",
            "molecularProfile": {
                "id": 16574,
                "profileName": "FBXW7 mutant"
            },
            "therapy": {
                "id": 2958,
                "therapyName": "LY3039478",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12806,
                    "pubMedId": 30060061,
                    "title": "First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30060061"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15216,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (MATCH) trial, Capivasertib (AZD5363) treatment resulted in partial response in 23% (8/35) of patients with advanced solid tumors harboring AKT1 E17K mutation, 6 of the patients achieved partial response had hormone receptor-positive, Erbb2 (Her2)-negative breast cancer (PMID: 30429128; NCT02465060).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12850,
                    "pubMedId": 30429128,
                    "title": "Capivasertib Active against AKT1-Mutated Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30429128"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16227,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a clinical study, FGFR1 amplification was associated with resistance to Femara (letrozole) treatment in patients with ER-positive, ERBB2 (HER2)-negative breast cancer, with FGFR1 amplification observed in 43% (9/21) of letrozole-resistant tumors, compared to 7% (3/40) of sensitive tumors, and 10% (1/11) of intermediate tumors (resistant vs. intermediate and sensitive tumors, p=0.0011) (PMID: 28751448).",
            "molecularProfile": {
                "id": 13347,
                "profileName": "ESR1 pos FGFR1 amp"
            },
            "therapy": {
                "id": 794,
                "therapyName": "Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14363,
                    "pubMedId": 28751448,
                    "title": "Association of FGFR1 with ER\u03b1 Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751448"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16228,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a clinical study, FGF3, FGF4, and FGF19 were coamplified in 90% (8/9) of FGFR1-amplified tumors in patients with ER-positive, ERBB2 (HER2)-negative breast cancer, and the coamplification was associated with resistance to Femara (letrozole) treatment (p=0.0001) (PMID: 28751448).",
            "molecularProfile": {
                "id": 31564,
                "profileName": "ESR1 pos FGF19 amp FGF3 amp FGF4 amp FGFR1 amp"
            },
            "therapy": {
                "id": 794,
                "therapyName": "Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14363,
                    "pubMedId": 28751448,
                    "title": "Association of FGFR1 with ER\u03b1 Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751448"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16229,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lucitanib (E-3810) and Faslodex (fulvestrant) combination treatment demonstrated improved potency compared to single drug treatment, resulted in enhanced inhibition of downstream signaling and proliferation of FGFR1-amplified, ER-positive, ERBB2 (HER2)-negative breast cancer cells in culture, and inhibited tumor growth in patient-derived xenograft (PDX) models (PMID: 28751448).",
            "molecularProfile": {
                "id": 13347,
                "profileName": "ESR1 pos FGFR1 amp"
            },
            "therapy": {
                "id": 7952,
                "therapyName": "Fulvestrant + Lucitanib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14363,
                    "pubMedId": 28751448,
                    "title": "Association of FGFR1 with ER\u03b1 Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751448"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16256,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment demonstrated safety and preliminary efficacy, resulted in partial response in 12% (3/25) and stable disease in 16% (4/25) of patients with CD274 (PD-L1)-positive (combined positive score >=1) advanced ER-positive, ERBB2 (HER2)-negative breast cancer, with a median duration of response of 12.0 months (PMID: 29559561; NCT02054806).",
            "molecularProfile": {
                "id": 4746,
                "profileName": "CD274 positive"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14396,
                    "pubMedId": 29559561,
                    "title": "Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29559561"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16417,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, Nolvadex (tamoxifen) and Venclexta (venetoclax) combination treatment resulted in an objective response rate of 45% (15/33, 1 complete response, 14 partial response) and a clinical benefit rate of 70% (23/33) in patients with ER, BCL2-positive, ERBB2 (HER2)-nonamplified (negative) metastatic breast cancer, with a median duration of response of 42 weeks (PMID: 30518523).",
            "molecularProfile": {
                "id": 31628,
                "profileName": "BCL2 pos ESR1 pos"
            },
            "therapy": {
                "id": 8024,
                "therapyName": "Tamoxifen + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14490,
                    "pubMedId": 30518523,
                    "title": "A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30518523"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16713,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Chidamide (CS055) in combination with Aromasin (exemestane) resulted in improved progression-free survival (7.4 vs 3.7 months, HR=0.755, p=0.0336), objective response rate (18.4% vs 9.1%), and clinical benefit rate (46.7% vs 35.5%) compared to placebo in patients with hormone receptor positive, ERBB2 (HER2)-negative breast cancer patients (ESMO 2018 Congress, Oct 2018, Presidential Symposium 1; NCT02482753).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 8155,
                "therapyName": "Chidamide + Exemestane",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14746,
                    "pubMedId": null,
                    "title": "Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer",
                    "url": "https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Phase-III-trial-of-chidamide-a-subtype-selective-histone-deacetylase-HDAC-inhibitor-in-combination-with-exemestane-in-patients-with-ho"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16714,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Chidamide (CS055) in combination with Aromasin (exemestane) resulted in improved progression-free survival (7.4 vs 3.7 months, HR=0.755, p=0.0336), objective response rate (18.4% vs 9.1%), and clinical benefit rate (46.7% vs 35.5%) compared to placebo in patients with hormone receptor positive, ERBB2 (HER2)-negative breast cancer patients (ESMO 2018 Congress, Oct 2018, Presidential Symposium 1; NCT02482753).",
            "molecularProfile": {
                "id": 1856,
                "profileName": "PGR positive"
            },
            "therapy": {
                "id": 8155,
                "therapyName": "Chidamide + Exemestane",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14746,
                    "pubMedId": null,
                    "title": "Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer",
                    "url": "https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Phase-III-trial-of-chidamide-a-subtype-selective-histone-deacetylase-HDAC-inhibitor-in-combination-with-exemestane-in-patients-with-ho"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16872,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Xalkori (crizotinib) treatment resulted in imaging response and decreased tumor markers in a patient with ER/PR-positive, Erbbe2 (Her2)-negative breast cancer (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1317).",
            "molecularProfile": {
                "id": 10684,
                "profileName": "GOPC - ROS1"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14988,
                    "pubMedId": null,
                    "title": "Exceptional responses to crizotinib in breast cancer patients with somatic MET and ROS1 alterations.",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16873,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Xalkori (crizotinib) treatment resulted in clinical response in a patient with ER/PR-positive, Erbbe2 (Her2)-negative breast cancer (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1317).",
            "molecularProfile": {
                "id": 10684,
                "profileName": "GOPC - ROS1"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14988,
                    "pubMedId": null,
                    "title": "Exceptional responses to crizotinib in breast cancer patients with somatic MET and ROS1 alterations.",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16913,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (BOLERO-2) that supported FDA approval, the combination of Afinitor (everolimus) and Aromasin (exemestane) resulted in an improved median progression-free survival (7.8 vs 3.2 months) compared to Aromasin (exemestane) and placebo in patients with ERBB2 (HER2)-negative, hormone receptor-positive breast cancer whose disease recurred or progressed during or after nonsteroidal aromatase inhibitor therapy (PMID: 24158787; NCT00863655).",
            "molecularProfile": {
                "id": 1856,
                "profileName": "PGR positive"
            },
            "therapy": {
                "id": 1966,
                "therapyName": "Everolimus + Exemestane",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10766,
                    "pubMedId": 24158787,
                    "title": "Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24158787"
                },
                {
                    "id": 15547,
                    "pubMedId": null,
                    "title": "Afinitor (everolimus) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022334"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17125,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA C420R (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 26988,
                "profileName": "ESR1 pos PIK3CA C420R"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17126,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA E542K (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 26989,
                "profileName": "ESR1 pos PIK3CA E542K"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17127,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA E545A (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34221,
                "profileName": "ESR1 pos PIK3CA E545A"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17128,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA E545D (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34222,
                "profileName": "ESR1 pos PIK3CA E545D"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17129,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA E545G (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34223,
                "profileName": "ESR1 pos PIK3CA E545G"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17130,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA E545K (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 20267,
                "profileName": "ESR1 pos PIK3CA E545K"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17131,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA Q546R (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34224,
                "profileName": "ESR1 pos PIK3CA Q546R"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17132,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA Q546E (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34225,
                "profileName": "ESR1 pos PIK3CA Q546E"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17133,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA H1047L (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34226,
                "profileName": "ESR1 pos PIK3CA H1047L"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17134,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA H1047R (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 20269,
                "profileName": "ESR1 pos PIK3CA H1047R"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17135,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA H1047Y (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34227,
                "profileName": "ESR1 pos PIK3CA H1047Y"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17718,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (NEO-ORB), Piqray (Alpelisib) and Femara (letrozole) combination treatment in the neoadjuvant setteing did not improve objective response rate (26/40, 43.3% vs 30/67, 44.8%) or pathologic complete response rate (1/60, 1.7% vs 2/67, 3.0%) compared to Femara (letrozole) plus placebo in patients with hormone receptor-positive, ERBB2 (HER2)-negative, PIK3CA mutant breast cancer (PMID: 30723140; NCT01923168).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 1553,
                "therapyName": "Alpelisib + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 15751,
                    "pubMedId": 30723140,
                    "title": "A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30723140"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17719,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (NEO-ORB), Piqray (Alpelisib) and Femara (letrozole) combination treatment in the neoadjuvant setteing did not improve objective response rate (26/40, 43.3% vs 30/67, 44.8%) or pathologic complete response rate (1/60, 1.7% vs 2/67, 3.0%) compared to Femara (letrozole) plus placebo in patients with hormone receptor-positive, ERBB2 (HER2)-negative, PIK3CA mutant breast cancer (PMID: 30723140; NCT01923168).",
            "molecularProfile": {
                "id": 32749,
                "profileName": "PGR pos PIK3CA mut"
            },
            "therapy": {
                "id": 1553,
                "therapyName": "Alpelisib + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 15751,
                    "pubMedId": 30723140,
                    "title": "A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30723140"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17723,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (NEO-ORB), Piqray (Alpelisib) and Femara (letrozole) combination treatment in the neoadjuvant setteing did not improve objective response rate (45/71, 63.4% vs 36/59, 61.0%) or pathologic complete response rate (2/71, 2.8% vs 1/59, 1.7%) compared to Femara (letrozole) plus placebo in patients with hormone receptor-positive, ERBB2 (HER2)-negative, PIK3CA wild-type breast cancer (PMID: 30723140; NCT01923168).",
            "molecularProfile": {
                "id": 21969,
                "profileName": "ESR1 pos PIK3CA wild-type"
            },
            "therapy": {
                "id": 1553,
                "therapyName": "Alpelisib + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 15751,
                    "pubMedId": 30723140,
                    "title": "A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30723140"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17724,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (NEO-ORB), Piqray (Alpelisib) and Femara (letrozole) combination treatment in the neoadjuvant setteing did not improve objective response rate (45/71, 63.4% vs 36/59, 61.0%) or pathologic complete response rate (2/71, 2.8% vs 1/59, 1.7%) compared to Femara (letrozole) plus placebo in patients with hormone receptor-positive, ERBB2 (HER2)-negative, PIK3CA wild-type breast cancer (PMID: 30723140; NCT01923168).",
            "molecularProfile": {
                "id": 32754,
                "profileName": "PGR pos PIK3CA wild-type"
            },
            "therapy": {
                "id": 1553,
                "therapyName": "Alpelisib + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 15751,
                    "pubMedId": 30723140,
                    "title": "A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30723140"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17744,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, MK2206 treatment resulted in a partial response in a patient with ER-positive, PR-negative, and ERBB2 (HER2)-negative breast cancer harboring PIK3CA E542K and KRAS G12S, the patient remained on study for 36 weeks (PMID: 31277699; NCT01277757).",
            "molecularProfile": {
                "id": 32786,
                "profileName": "KRAS G12S PIK3CA E542K"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15758,
                    "pubMedId": 31277699,
                    "title": "Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31277699"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18276,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), CCND1 expression level did not correlate with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.471 and 0.594 (p=0.503) in CCND1 low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33094,
                "profileName": "CCND1 pos ESR1 pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18277,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), CCND1 expression level did not correlate with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.471 and 0.594 (p=0.503) in CCND1 low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33095,
                "profileName": "CCND1 pos PGR pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18278,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), CDK4 expression level did not correlate with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.509 and 0.562 (p=0.627) in CDK4 low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33096,
                "profileName": "CDK4 pos ESR1 pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18279,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), CDK4 expression level did not correlate with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.509 and 0.562 (p=0.627) in CDK4 low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33097,
                "profileName": "CDK4 pos PGR pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18280,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), CDK6 expression level did not correlate with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.605 and 0.483 (p=0.515) in CDK6 low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33098,
                "profileName": "CDK6 pos ESR1 pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18281,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), CDK6 expression level did not correlate with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.605 and 0.483 (p=0.515) in CDK6 low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33099,
                "profileName": "CDK6 pos PGR pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18282,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), RB1 expression level did not correlate with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.425 and 0.672 (p=0.123) in RB1 low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33100,
                "profileName": "ESR1 pos RB1 pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18283,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), RB1 expression level did not correlate with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.425 and 0.672 (p=0.123) in RB1 low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33101,
                "profileName": "PGR pos RB1 pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18284,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), CDKN2A expression level did not correlate with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.504 and 0.555 (p=0.730) in CDKN2A low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33112,
                "profileName": "CDKN2A pos ESR1 pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18285,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), CDKN2A expression level did not correlate with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.504 and 0.555 (p=0.730) in CDKN2A low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33111,
                "profileName": "CDKN2A pos PGR pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18286,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), CCNE2 expression level did not correlate with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.513 and 0.560 (p=0.834) in CCNE2 low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33115,
                "profileName": "CCNE2 pos ESR1 pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18287,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), CCNE2 expression level did not correlate with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.513 and 0.560 (p=0.834) in CCNE2 low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33116,
                "profileName": "CCNE2 pos PGR pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18289,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), CCNE1 expression level negatively correlates with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.320 and 0.851 (p=0.00238) in CCNE1 low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33102,
                "profileName": "CCNE1 pos ESR1 pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18290,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), CCNE1 expression level negatively correlates with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.320 and 0.851 (p=0.00238) in CCNE1 low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33103,
                "profileName": "CCNE1 pos PGR pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18295,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PALOMA-1/TRIO-18), CCND1 amplification and/or CDKN2A loss did not correlate with response to addition of Ibrance (palbociclib) to Femara (letrozole) in patients with estrogen receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.37 and 0.19 (p=0.13) in patients with or without CCND1 amplification and/or CDKN2A loss, respectively (PMID: 25524798; NCT00721409).",
            "molecularProfile": {
                "id": 21974,
                "profileName": "CCND1 amp ESR1 pos"
            },
            "therapy": {
                "id": 2922,
                "therapyName": "Letrozole + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16122,
                    "pubMedId": 25524798,
                    "title": "The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25524798"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18296,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PALOMA-1/TRIO-18), CCND1 amplification and/or CDKN2A loss did not correlate with response to addition of Ibrance (palbociclib) to Femara (letrozole) in patients with estrogen receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.37 and 0.19 (p=0.13) in patients with or without CCND1 amplification and/or CDKN2A loss, respectively (PMID: 25524798; NCT00721409).",
            "molecularProfile": {
                "id": 33130,
                "profileName": "CDKN2A loss ESR1 pos"
            },
            "therapy": {
                "id": 2922,
                "therapyName": "Letrozole + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16122,
                    "pubMedId": 25524798,
                    "title": "The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25524798"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18810,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "The combination of Faslodex (fulvestrant) and Piqray (alpelisib) is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-negative breast cancer harboring a PIK3CA mutation (NCCN.org).",
            "molecularProfile": {
                "id": 33604,
                "profileName": "ESR1 pos PGR pos PIK3CA mut"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19312,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase III trial (BOLERO-2), the presence of PIK3CA mutations did not significantly affect the efficacy of Afinitor (everolimus) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with a HR for progression-free survival of 0.37 in PIK3CA wild-type group and a HR of 0.51 (p=0.35) in patients with PIK3CA mutations (PMID: 26503204; NCT00863655).",
            "molecularProfile": {
                "id": 429,
                "profileName": "PIK3CA mutant"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16925,
                    "pubMedId": 26503204,
                    "title": "Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26503204"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19313,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase III trial (BOLERO-2), Afinitor (everolimus) demonstrated greater benefit on progression-free survival in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer harboring PIK3CA exon 9 mutations (HR=0.26) compared to patients harboring PIK3CA exon 20 mutations (HR=0.56) (PMID: 26503204; NCT00863655).",
            "molecularProfile": {
                "id": 34050,
                "profileName": "PIK3CA exon9"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16925,
                    "pubMedId": 26503204,
                    "title": "Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26503204"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19314,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase III trial (BOLERO-2), Afinitor (everolimus) demonstrated greater benefit on progression-free survival in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer harboring PIK3CA exon 9 mutations (HR=0.26) compared to patients harboring PIK3CA exon 20 mutations (HR=0.56) (PMID: 26503204; NCT00863655).",
            "molecularProfile": {
                "id": 34044,
                "profileName": "PIK3CA exon20"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16925,
                    "pubMedId": 26503204,
                    "title": "Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26503204"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19315,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase III trial (BOLERO-2), Afinitor (everolimus) demonstrated comparable progression-free survival benefit in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer harboring wild-type (HR=0.43) or mutant (HR=0.37) PIK3CA, similar benefit was observed in subgroups harboring PIK3CA H1047R (HR=0.37) and PIK3CA E545K/E542K (HR=0.30) (PMID: 28183140; NCT00863655).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10362,
                    "pubMedId": 28183140,
                    "title": "Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28183140"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19316,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase III trial (BOLERO-2), Afinitor (everolimus) demonstrated comparable progression-free survival benefit in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer harboring wild-type (HR=0.43) or mutant (HR=0.37) PIK3CA, similar benefit was observed in subgroups harboring PIK3CA H1047R (HR=0.37) and PIK3CA E545K/E542K (HR=0.30) (PMID: 28183140; NCT00863655).",
            "molecularProfile": {
                "id": 2421,
                "profileName": "PIK3CA E545K"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10362,
                    "pubMedId": 28183140,
                    "title": "Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28183140"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19317,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase III trial (BOLERO-2), Afinitor (everolimus) demonstrated comparable progression-free survival benefit in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer harboring wild-type (HR=0.43) or mutant (HR=0.37) PIK3CA, similar benefit was observed in subgroups harboring PIK3CA H1047R (HR=0.37) and PIK3CA E545K/E542K (HR=0.30) (PMID: 28183140; NCT00863655).",
            "molecularProfile": {
                "id": 808,
                "profileName": "PIK3CA E542K"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10362,
                    "pubMedId": 28183140,
                    "title": "Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28183140"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19572,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "The combination of Faslodex (fulvestrant) and Piqray (alpelisib) is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-negative breast cancer harboring a PIK3CA mutation (NCCN.org).",
            "molecularProfile": {
                "id": 32749,
                "profileName": "PGR pos PIK3CA mut"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19571,
            "approvalStatus": "FDA approved - Has Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 32749,
                "profileName": "PGR pos PIK3CA mut"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19573,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA C420R (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34229,
                "profileName": "PGR pos PIK3CA C420R"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19574,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA E542K (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34230,
                "profileName": "PGR pos PIK3CA E542K"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19575,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA E545A (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34231,
                "profileName": "PGR pos PIK3CA E545A"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19576,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA E545D (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34232,
                "profileName": "PGR pos PIK3CA E545D"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19577,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA E545G (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34233,
                "profileName": "PGR pos PIK3CA E545G"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19578,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA E545K (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34234,
                "profileName": "PGR pos PIK3CA E545K"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19579,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA H1047L (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34235,
                "profileName": "PGR pos PIK3CA H1047L"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19580,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA H1047R (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34236,
                "profileName": "PGR pos PIK3CA H1047R"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19581,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA H1047Y (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34237,
                "profileName": "PGR pos PIK3CA H1047Y"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19582,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA Q546E (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34238,
                "profileName": "PGR pos PIK3CA Q546E"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19583,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA Q546R (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34239,
                "profileName": "PGR pos PIK3CA Q546R"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20060,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tykerb (lapatinib) combined with Xeloda (capecitabine) is included in guidelines as systemic therapy for patients with recurrent or metastatic hormone receptor-positive (ER and/or PR) or negative, ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 1399,
                "therapyName": "Capecitabine + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20154,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (FINESSE) trial, Lucitanib (E-3810) treatment resulted in an objective response rate (ORR) of 19% (6/32) and a clinical benefit rate of 41% (13/32) in patients with metastatic hormone receptor-positive, Erbb2 (Her2)-negative breast cancer harboring FGFR1 amplification, ORR was improved (22%, 5/23 vs 9%, 5/53) in patients with high level FGFR1 amplification (FGFR1/centromere ratio>=4) compared to those without (PMID: 31619444; NCT02053636).",
            "molecularProfile": {
                "id": 812,
                "profileName": "FGFR1 amp"
            },
            "therapy": {
                "id": 1029,
                "therapyName": "Lucitanib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17719,
                    "pubMedId": 31619444,
                    "title": "Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31619444"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20155,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (FINESSE) trial, Lucitanib (E-3810) treatment resulted in an objective response rate (ORR) of 0% (0/18) and a clinical benefit rate of 11% (2/18) in patients with metastatic hormone receptor-positive, Erbb2 (Her2)-negative breast cancer harboring 11q13 (containing FGF3, FGF4, FGF19, and CCND1) amplification but not FGFR1 amplification, 11q13 amplification was associated with poor response (7%, 2/29) in biomarker analysis (PMID: 31619444; NCT02053636).",
            "molecularProfile": {
                "id": 34910,
                "profileName": "CCND1 amp FGF19 amp FGF3 amp FGF4 amp"
            },
            "therapy": {
                "id": 1029,
                "therapyName": "Lucitanib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 17719,
                    "pubMedId": 31619444,
                    "title": "Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31619444"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20156,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (FINESSE) trial, Lucitanib (E-3810) treatment resulted in improved objective response rate (25%, 5/20 vs 8%, 3/39) and median progression-free survival (158 vs 109 days) in patients with metastatic hormone receptor-positive, Erbb2 (Her2)-negative breast cancer with high Fgfr1 expression (H-score>=50) compared to those with low Fgfr1 expression (H-score<50) (PMID: 31619444; NCT02053636).",
            "molecularProfile": {
                "id": 4208,
                "profileName": "FGFR1 over exp"
            },
            "therapy": {
                "id": 1029,
                "therapyName": "Lucitanib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17719,
                    "pubMedId": 31619444,
                    "title": "Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31619444"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20157,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (FINESSE) trial, Fgf2 expression was not correlated with progression-free survival in patients with metastatic hormone receptor-positive, Erbb2 (Her2)-negative breast cancer treated with Lucitanib (E-3810) (PMID: 31619444; NCT02053636).",
            "molecularProfile": {
                "id": 26858,
                "profileName": "FGF2 positive"
            },
            "therapy": {
                "id": 1029,
                "therapyName": "Lucitanib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 17719,
                    "pubMedId": 31619444,
                    "title": "Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31619444"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20390,
            "approvalStatus": "Phase 0",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase 0/I trial, addition of ME-344 to Avastin (bevacizumab) treatment resulted in a 23.4% decrease of Ki67 in treatment-naive patients with early-stage Erbb2 (Her2)-negative breast cancer, compared to a 186% increase in the placebo arm (PMID: 31597662; NCT02806817).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1970,
                "therapyName": "ME-344",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17827,
                    "pubMedId": 31597662,
                    "title": "Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31597662"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 21190,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, FR alpha peptide vaccine demonstrated safety, induced durable immune response against Folr1 in hormone receptor-positive, ERBB2 (HER2)-negative breast cancer patients who completed standard treatment, and all patients (n=8) remained alive 2 years after initial immunization, with a median relapse-free survival not reached; however, T cell response did not correlate with tumor Folr1 expression level (PMID: 29545464; NCT01606241).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 9587,
                "therapyName": "FR alpha peptide vaccine",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 18453,
                    "pubMedId": 29545464,
                    "title": "Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29545464"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00764972",
            "title": "Phase IB/II Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 2357,
                    "therapyName": "Sorafenib + Vinorelbine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00921115",
            "title": "Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 633,
                    "therapyName": "Anastrozole",
                    "synonyms": null
                },
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00971737",
            "title": "Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01036087",
            "title": "Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1984,
                    "therapyName": "Carboplatin + Nab-paclitaxel + Panitumumab",
                    "synonyms": null
                },
                {
                    "id": 1982,
                    "therapyName": "Cyclophosphamide + Epirubicin + Fluorouracil",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01116648",
            "title": "Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                },
                {
                    "id": 1971,
                    "therapyName": "Cediranib + Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01145430",
            "title": "Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2167,
                    "therapyName": "Pegylated liposomal-doxorubicin + Veliparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01262027",
            "title": "TKI258 for Metastatic Inflammatory Breast Cancer Patients",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 721,
                    "therapyName": "Dovitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01272037",
            "title": "Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 633,
                    "therapyName": "Anastrozole",
                    "synonyms": null
                },
                {
                    "id": 794,
                    "therapyName": "Letrozole",
                    "synonyms": null
                },
                {
                    "id": 1456,
                    "therapyName": "Tamoxifen",
                    "synonyms": null
                },
                {
                    "id": 738,
                    "therapyName": "Exemestane",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01292655",
            "title": "Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2545,
                    "therapyName": "BMS-906024",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01351909",
            "title": "Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 954,
                    "therapyName": "Veliparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01437566",
            "title": "Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 750,
                    "therapyName": "GDC-0980",
                    "synonyms": null
                },
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                },
                {
                    "id": 749,
                    "therapyName": "Pictilisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01441947",
            "title": "Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1965,
                    "therapyName": "Cabozantinib + Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01467310",
            "title": "Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01479244",
            "title": "Efficacy and Safety Study of NeuVax (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3766,
                    "therapyName": "E75",
                    "synonyms": null
                },
                {
                    "id": 1873,
                    "therapyName": "Sargramostim",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01484041",
            "title": "Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 721,
                    "therapyName": "Dovitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01528345",
            "title": "Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2189,
                    "therapyName": "Dovitinib + Fulvestrant",
                    "synonyms": null
                },
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01560416",
            "title": "Fulvestrant With or Without Ganetespib in HR+ Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                },
                {
                    "id": 745,
                    "therapyName": "Ganetespib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01572727",
            "title": "A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1545,
                    "therapyName": "Buparlisib + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01610284",
            "title": "Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor (BELLE-2)r",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1546,
                    "therapyName": "Buparlisib + Fulvestrant",
                    "synonyms": null
                },
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01633060",
            "title": "A Phase III Study of BKM120 With Fulvestrant in Patients With HR+, HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi",
            "phase": "Phase III",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                },
                {
                    "id": 1546,
                    "therapyName": "Buparlisib + Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01670877",
            "title": "Neratinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 828,
                    "therapyName": "Neratinib",
                    "synonyms": null
                },
                {
                    "id": 5705,
                    "therapyName": "Fulvestrant + Neratinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01674140",
            "title": "S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 759,
                    "therapyName": "Goserelin",
                    "synonyms": null
                },
                {
                    "id": 633,
                    "therapyName": "Anastrozole",
                    "synonyms": null
                },
                {
                    "id": 794,
                    "therapyName": "Letrozole",
                    "synonyms": null
                },
                {
                    "id": 795,
                    "therapyName": "Leuprolide",
                    "synonyms": null
                },
                {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                },
                {
                    "id": 1456,
                    "therapyName": "Tamoxifen",
                    "synonyms": null
                },
                {
                    "id": 738,
                    "therapyName": "Exemestane",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01698918",
            "title": "Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1966,
                    "therapyName": "Everolimus + Exemestane",
                    "synonyms": null
                },
                {
                    "id": 1621,
                    "therapyName": "Everolimus + Letrozole",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01757327",
            "title": "LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1428,
                    "therapyName": "Sonidegib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01776008",
            "title": "Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1548,
                    "therapyName": "Goserelin + MK2206",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01779050",
            "title": "Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 1087,
                    "therapyName": "Cyclophosphamide + Epirubicin",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1982,
                    "therapyName": "Cyclophosphamide + Epirubicin + Fluorouracil",
                    "synonyms": null
                },
                {
                    "id": 1834,
                    "therapyName": "Carboplatin + Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 1881,
                    "therapyName": "Cyclophosphamide + Docetaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01791478",
            "title": "BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1553,
                    "therapyName": "Alpelisib + Letrozole",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01792050",
            "title": "Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 2976,
                    "therapyName": "Indoximod",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01797120",
            "title": "Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1589,
                    "therapyName": "Everolimus + Fulvestrant",
                    "synonyms": null
                },
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01803282",
            "title": "Safety and Tolerability Study in Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3320,
                    "therapyName": "GS-5745",
                    "synonyms": null
                },
                {
                    "id": 1161,
                    "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1602,
                    "therapyName": "Carboplatin + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 1315,
                    "therapyName": "Fluorouracil + Irinotecan + Leucovorin",
                    "synonyms": "FOLFIRI"
                },
                {
                    "id": 1779,
                    "therapyName": "Gemcitabine + Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01823835",
            "title": "A Study of ARN-810 (GDC-0810) in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2150,
                    "therapyName": "GDC-0810",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01837602",
            "title": "cMet CAR RNA T Cells Targeting Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT01894451",
            "title": "Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01905592",
            "title": "A Phase III Trial of Niraparib Versus Physician's Choice in Her2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients (BRAVO)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 832,
                    "therapyName": "Niraparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01918306",
            "title": "GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 1554,
                    "therapyName": "Cisplatin + Pictilisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01923168",
            "title": "Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1570,
                    "therapyName": "Buparlisib + Letrozole",
                    "synonyms": null
                },
                {
                    "id": 794,
                    "therapyName": "Letrozole",
                    "synonyms": null
                },
                {
                    "id": 1553,
                    "therapyName": "Alpelisib + Letrozole",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01953588",
            "title": "Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 633,
                    "therapyName": "Anastrozole",
                    "synonyms": null
                },
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01958021",
            "title": "Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) (MONALEESA-2)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1568,
                    "therapyName": "Letrozole + Ribociclib",
                    "synonyms": null
                },
                {
                    "id": 794,
                    "therapyName": "Letrozole",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01963481",
            "title": "Exemestane and Cyclophosphamide for Metastatic Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 738,
                    "therapyName": "Exemestane",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01964924",
            "title": "Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1298,
                    "therapyName": "Trametinib + Uprosertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01969643",
            "title": "A Safety Study of SGN-LIV1A in Breast Cancer Patients",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3615,
                    "therapyName": "SGN-LIV1A",
                    "synonyms": null
                },
                {
                    "id": 8264,
                    "therapyName": "SGN-LIV1A  + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02010021",
            "title": "Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 794,
                    "therapyName": "Letrozole",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02032277",
            "title": "A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1977,
                    "therapyName": "Cyclophosphamide + Doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 954,
                    "therapyName": "Veliparib",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02032823",
            "title": "Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02038699",
            "title": "A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1687,
                    "therapyName": "ONC201",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02049957",
            "title": "Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1581,
                    "therapyName": "Fulvestrant + Sapanisertib",
                    "synonyms": null
                },
                {
                    "id": 1580,
                    "therapyName": "Exemestane + Sapanisertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02057133",
            "title": "A Study of LY2835219 in Combination With Hormone Therapies for Breast Cancer That Has Spread",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8265,
                    "therapyName": "Abemaciclib + Loperamide + Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 8266,
                    "therapyName": "Abemaciclib + Fulvestrant + LY3023414",
                    "synonyms": null
                },
                {
                    "id": 2254,
                    "therapyName": "Abemaciclib + Letrozole",
                    "synonyms": null
                },
                {
                    "id": 2257,
                    "therapyName": "Abemaciclib + Exemestane",
                    "synonyms": null
                },
                {
                    "id": 802,
                    "therapyName": "Abemaciclib",
                    "synonyms": null
                },
                {
                    "id": 2258,
                    "therapyName": "Abemaciclib + Everolimus + Exemestane",
                    "synonyms": null
                },
                {
                    "id": 2255,
                    "therapyName": "Abemaciclib + Anastrozole",
                    "synonyms": null
                },
                {
                    "id": 2256,
                    "therapyName": "Abemaciclib + Tamoxifen",
                    "synonyms": null
                },
                {
                    "id": 2259,
                    "therapyName": "Abemaciclib + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02074878",
            "title": "CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1962,
                    "therapyName": "Crizotinib + Sunitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02088684",
            "title": "Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2315,
                    "therapyName": "Buparlisib + Fulvestrant + Ribociclib",
                    "synonyms": null
                },
                {
                    "id": 2316,
                    "therapyName": "Fulvestrant + Ribociclib",
                    "synonyms": null
                },
                {
                    "id": 2317,
                    "therapyName": "Alpelisib + Fulvestrant + Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02095184",
            "title": "GCC 1366 Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients",
            "phase": "Phase 0",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 633,
                    "therapyName": "Anastrozole",
                    "synonyms": null
                },
                {
                    "id": 794,
                    "therapyName": "Letrozole",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02107703",
            "title": "A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer (MONARCH 2)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5859,
                    "therapyName": "Abemaciclib + Fulvestrant",
                    "synonyms": null
                },
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02115048",
            "title": "Clinical Study for the Treatment of Breast Cancer the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 623,
                    "therapyName": "Afatinib",
                    "synonyms": null
                },
                {
                    "id": 794,
                    "therapyName": "Letrozole",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02120417",
            "title": "A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1615,
                    "therapyName": "Capecitabine + Ruxolitinib",
                    "synonyms": null
                },
                {
                    "id": 1105,
                    "therapyName": "Capecitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02137837",
            "title": "S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer",
            "phase": "Phase III",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1589,
                    "therapyName": "Everolimus + Fulvestrant",
                    "synonyms": null
                },
                {
                    "id": 1590,
                    "therapyName": "Anastrozole + Everolimus + Fulvestrant",
                    "synonyms": null
                },
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02142868",
            "title": "Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate",
            "phase": "Phase III",
            "recruitment": "No longer available",
            "therapies": [
                {
                    "id": 2922,
                    "therapyName": "Letrozole + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02154776",
            "title": "Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. (LeeBLet)",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1594,
                    "therapyName": "Buparlisib + Letrozole + Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02157051",
            "title": "Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT02163694",
            "title": "A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5274,
                    "therapyName": "Carboplatin + Paclitaxel + Veliparib",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02178722",
            "title": "A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4088,
                    "therapyName": "Epacadostat + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02187991",
            "title": "Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1679,
                    "therapyName": "Alisertib + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02188745",
            "title": "ER Reactivation Therapy for Breast Cancer (POLLY)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 738,
                    "therapyName": "Exemestane",
                    "synonyms": null
                },
                {
                    "id": 1643,
                    "therapyName": "Estradiol",
                    "synonyms": null
                },
                {
                    "id": 633,
                    "therapyName": "Anastrozole",
                    "synonyms": null
                },
                {
                    "id": 794,
                    "therapyName": "Letrozole",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02204098",
            "title": "Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8308,
                    "therapyName": "Mammaglobin-A",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02236572",
            "title": "Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02246621",
            "title": "A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1854,
                    "therapyName": "Abemaciclib + Anastrozole + Letrozole",
                    "synonyms": null
                },
                {
                    "id": 1853,
                    "therapyName": "Anastrozole + Letrozole",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02248090",
            "title": "AZD9496 First Time in Patients Ascending Dose Study",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2997,
                    "therapyName": "AZD9496",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02258451",
            "title": "Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1966,
                    "therapyName": "Everolimus + Exemestane",
                    "synonyms": null
                },
                {
                    "id": 2001,
                    "therapyName": "Radium Ra 223 dichloride",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02258464",
            "title": "Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2001,
                    "therapyName": "Radium Ra 223 dichloride",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02259114",
            "title": "A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2034,
                    "therapyName": "Birabresib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02260661",
            "title": "Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                },
                {
                    "id": 2013,
                    "therapyName": "AZD8835",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02269670",
            "title": "Phase II Study of Everolimus Beyond Progression",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1456,
                    "therapyName": "Tamoxifen",
                    "synonyms": null
                },
                {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                },
                {
                    "id": 1869,
                    "therapyName": "Megestrol acetate",
                    "synonyms": null
                },
                {
                    "id": 794,
                    "therapyName": "Letrozole",
                    "synonyms": null
                },
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                },
                {
                    "id": 633,
                    "therapyName": "Anastrozole",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02273752",
            "title": "Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02273973",
            "title": "Study of Neoadjuvant Letrozole + GDC-0032 Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1016,
                    "therapyName": "Taselisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02276443",
            "title": "Molecular Triaging and Diagnostic Imaging to Guide Neoadjuvant Therapy",
            "phase": null,
            "recruitment": "Recruiting",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT02278120",
            "title": "Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (MONALEESA-7)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 8386,
                    "therapyName": "Goserelin + Ribociclib",
                    "synonyms": null
                },
                {
                    "id": 1456,
                    "therapyName": "Tamoxifen",
                    "synonyms": null
                },
                {
                    "id": 794,
                    "therapyName": "Letrozole",
                    "synonyms": null
                },
                {
                    "id": 759,
                    "therapyName": "Goserelin",
                    "synonyms": null
                },
                {
                    "id": 633,
                    "therapyName": "Anastrozole",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02282345",
            "title": "Neoadjuvant Talazoparib for Patients With a BRCA Deleterious Mutation",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 682,
                    "therapyName": "Talazoparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02286843",
            "title": "Can HER2 Targeted 89Zr-trastuzumab PET/CT Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02291913",
            "title": "Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2267,
                    "therapyName": "Everolimus + Tamoxifen",
                    "synonyms": null
                },
                {
                    "id": 2268,
                    "therapyName": "Anastrozole + Everolimus",
                    "synonyms": null
                },
                {
                    "id": 1589,
                    "therapyName": "Everolimus + Fulvestrant",
                    "synonyms": null
                },
                {
                    "id": 1621,
                    "therapyName": "Everolimus + Letrozole",
                    "synonyms": null
                },
                {
                    "id": 2269,
                    "therapyName": "Everolimus + Toremifene",
                    "synonyms": null
                },
                {
                    "id": 1966,
                    "therapyName": "Everolimus + Exemestane",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02296801",
            "title": "A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 794,
                    "therapyName": "Letrozole",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02301988",
            "title": "A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 747,
                    "therapyName": "Ipatasertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02308020",
            "title": "A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 802,
                    "therapyName": "Abemaciclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02309177",
            "title": "Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 2489,
                    "therapyName": "Nab-paclitaxel + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02311933",
            "title": "Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3076,
                    "therapyName": "Z-endoxifen HCl",
                    "synonyms": null
                },
                {
                    "id": 1456,
                    "therapyName": "Tamoxifen",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02323191",
            "title": "A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7438,
                    "therapyName": "Atezolizumab + Emactuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02352025",
            "title": "S-equol in Women With Triple Negative Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2596,
                    "therapyName": "S-equol",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02374099",
            "title": "Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 651,
                    "therapyName": "Azacitidine",
                    "synonyms": null
                },
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02379247",
            "title": "BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2503,
                    "therapyName": "Alpelisib + Nab-paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02384239",
            "title": "A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3205,
                    "therapyName": "Fulvestrant + Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 3542,
                    "therapyName": "Palbociclib + Tamoxifen",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02384746",
            "title": "Phase I Study of the Combination of MLN9708 and Fulvestrant",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2568,
                    "therapyName": "Fulvestrant + Ixazomib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02389764",
            "title": "Nintedanib For HER2-negative Metastatic Inflammatory Breast Cancer (MIBC)",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 831,
                    "therapyName": "Nintedanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02401347",
            "title": "Phase II Talazoparib in BRCA1 +BRCA2 Wild-Type &Triple-Neg /HER2-Negative Breast Cancer /SolidTumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 682,
                    "therapyName": "Talazoparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02402764",
            "title": "Phase 2 Trial of Selinexor (KPT-330) for Metastatic TNBC",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1749,
                    "therapyName": "Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02403271",
            "title": "A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2573,
                    "therapyName": "Durvalumab + Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02422615",
            "title": "Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. (MONALEESA-3)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                },
                {
                    "id": 2316,
                    "therapyName": "Fulvestrant + Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02437318",
            "title": "Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 691,
                    "therapyName": "Alpelisib",
                    "synonyms": null
                },
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02441946",
            "title": "A Phase 2 Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 802,
                    "therapyName": "Abemaciclib",
                    "synonyms": null
                },
                {
                    "id": 2700,
                    "therapyName": "Loperamide",
                    "synonyms": null
                },
                {
                    "id": 633,
                    "therapyName": "Anastrozole",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02448771",
            "title": "A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2738,
                    "therapyName": "Bazedoxifene + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02453620",
            "title": "Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7450,
                    "therapyName": "Entinostat + Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02457910",
            "title": "Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1262,
                    "therapyName": "Enzalutamide",
                    "synonyms": null
                },
                {
                    "id": 8345,
                    "therapyName": "Enzalutamide + Taselisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02463032",
            "title": "Efficacy and Safety of GTx-024 in Patients With ER+/AR+ Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5026,
                    "therapyName": "enobosarm",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02476786",
            "title": "Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 633,
                    "therapyName": "Anastrozole",
                    "synonyms": null
                },
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                },
                {
                    "id": 759,
                    "therapyName": "Goserelin",
                    "synonyms": null
                },
                {
                    "id": 1456,
                    "therapyName": "Tamoxifen",
                    "synonyms": null
                },
                {
                    "id": 738,
                    "therapyName": "Exemestane",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02481050",
            "title": "Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 728,
                    "therapyName": "Eribulin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02513394",
            "title": "PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer (PALLAS)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02520063",
            "title": "Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 8283,
                    "therapyName": "Carotuximab + Everolimus + Letrozole",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02536794",
            "title": "MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02561832",
            "title": "A Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin in Patients With HER-2 Negative Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02575781",
            "title": "A Study of SAR428926 in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4026,
                    "therapyName": "SAR428926",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02586675",
            "title": "TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 759,
                    "therapyName": "Goserelin",
                    "synonyms": null
                },
                {
                    "id": 3175,
                    "therapyName": "Ribociclib + Tamoxifen",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02599714",
            "title": "Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (PASTOR)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3205,
                    "therapyName": "Fulvestrant + Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 991,
                    "therapyName": "Vistusertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02619669",
            "title": "Neoadjuvant Run-In Study With TAK-228 (MLN0128) Followed by Letrozole/TAK-228 (MLN0128) in Women With High-Risk ER+/HER2- Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1282,
                    "therapyName": "Sapanisertib",
                    "synonyms": null
                },
                {
                    "id": 794,
                    "therapyName": "Letrozole",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02626507",
            "title": "Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 1040,
                    "therapyName": "Gedatolisib",
                    "synonyms": null
                },
                {
                    "id": 759,
                    "therapyName": "Goserelin",
                    "synonyms": null
                },
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02630693",
            "title": "Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                },
                {
                    "id": 1456,
                    "therapyName": "Tamoxifen",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02632045",
            "title": "Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer (MAINTAIN)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2316,
                    "therapyName": "Fulvestrant + Ribociclib",
                    "synonyms": null
                },
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02648477",
            "title": "Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 8298,
                    "therapyName": "Letrozole + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 8297,
                    "therapyName": "Exemestane + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 8296,
                    "therapyName": "Anastrozole + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 4690,
                    "therapyName": "Doxorubicin + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02651610",
            "title": "Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 3545,
                    "therapyName": "Bavituximab",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02668666",
            "title": "Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3542,
                    "therapyName": "Palbociclib + Tamoxifen",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02684032",
            "title": "A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 794,
                    "therapyName": "Letrozole",
                    "synonyms": null
                },
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                },
                {
                    "id": 4034,
                    "therapyName": "Gedatolisib + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02692755",
            "title": "Palbociclib / Letrozole in African American Women With HR+ HER2- Breast Cancer (PALINA)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                },
                {
                    "id": 2922,
                    "therapyName": "Letrozole + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02712723",
            "title": "Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1568,
                    "therapyName": "Letrozole + Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02732119",
            "title": "Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. (TRINITI-1)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2265,
                    "therapyName": "Everolimus + Exemestane + Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02738866",
            "title": "Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3205,
                    "therapyName": "Fulvestrant + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02747004",
            "title": "A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (nextMONARCH 1)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4387,
                    "therapyName": "Abemaciclib + Loperamide",
                    "synonyms": null
                },
                {
                    "id": 802,
                    "therapyName": "Abemaciclib",
                    "synonyms": null
                },
                {
                    "id": 2256,
                    "therapyName": "Abemaciclib + Tamoxifen",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02752685",
            "title": "Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4023,
                    "therapyName": "Nab-paclitaxel + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02753686",
            "title": "Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy \u00b1 Targeted Therapy (Treat ER+ight)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1456,
                    "therapyName": "Tamoxifen",
                    "synonyms": null
                },
                {
                    "id": 738,
                    "therapyName": "Exemestane",
                    "synonyms": null
                },
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                },
                {
                    "id": 794,
                    "therapyName": "Letrozole",
                    "synonyms": null
                },
                {
                    "id": 633,
                    "therapyName": "Anastrozole",
                    "synonyms": null
                },
                {
                    "id": 1966,
                    "therapyName": "Everolimus + Exemestane",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02756364",
            "title": "MLN0128 in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1581,
                    "therapyName": "Fulvestrant + Sapanisertib",
                    "synonyms": null
                },
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02760030",
            "title": "Fulvestrant and Palbociclib in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3205,
                    "therapyName": "Fulvestrant + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02761694",
            "title": "ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8311,
                    "therapyName": "ARQ 751 + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 4331,
                    "therapyName": "ARQ 751",
                    "synonyms": null
                },
                {
                    "id": 8310,
                    "therapyName": "ARQ 751 + Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02764541",
            "title": "Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 3542,
                    "therapyName": "Palbociclib + Tamoxifen",
                    "synonyms": null
                },
                {
                    "id": 794,
                    "therapyName": "Letrozole",
                    "synonyms": null
                },
                {
                    "id": 1456,
                    "therapyName": "Tamoxifen",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02776917",
            "title": "Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4313,
                    "therapyName": "Cirmtuzumab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02778685",
            "title": "Pembrolizumab, Letrozole, and Palbociclib in Treating Patients With Stage IV Estrogen Receptor Positive Breast Cancer With Stable Disease That Has Not Responded to Letrozole and Palbociclib",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4222,
                    "therapyName": "Letrozole + Palbociclib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02779751",
            "title": "A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4242,
                    "therapyName": "Abemaciclib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02792114",
            "title": "T-Cell Therapy for Advanced Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5992,
                    "therapyName": "Rimiducid",
                    "synonyms": null
                },
                {
                    "id": 6029,
                    "therapyName": "Mesothelin CAR-T cells",
                    "synonyms": null
                },
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02792725",
            "title": "Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer",
            "phase": "Expanded access",
            "recruitment": "Approved for marketing",
            "therapies": [
                {
                    "id": 802,
                    "therapyName": "Abemaciclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02811497",
            "title": "Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4178,
                    "therapyName": "Azacitidine + Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02824575",
            "title": "Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4433,
                    "therapyName": "Paclitaxel + Rebastinib",
                    "synonyms": null
                },
                {
                    "id": 4434,
                    "therapyName": "Eribulin + Rebastinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02849496",
            "title": "Olaparib With or Without Atezolizumab in Treating Patients With Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                },
                {
                    "id": 8316,
                    "therapyName": "Atezolizumab + Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02860000",
            "title": "Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 4561,
                    "therapyName": "Alisertib + Fulvestrant",
                    "synonyms": null
                },
                {
                    "id": 626,
                    "therapyName": "Alisertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02871791",
            "title": "Palbociclib With Everolimus + Exemestane In BC",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4597,
                    "therapyName": "Everolimus + Exemestane + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02892734",
            "title": "Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02936206",
            "title": "Examination of Breast Cancer Cells of Pre-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1456,
                    "therapyName": "Tamoxifen",
                    "synonyms": null
                },
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02941926",
            "title": "Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1568,
                    "therapyName": "Letrozole + Ribociclib",
                    "synonyms": null
                },
                {
                    "id": 795,
                    "therapyName": "Leuprolide",
                    "synonyms": null
                },
                {
                    "id": 759,
                    "therapyName": "Goserelin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02942355",
            "title": "Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4974,
                    "therapyName": "Anastrozole + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02953860",
            "title": "Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4940,
                    "therapyName": "Enzalutamide + Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02955394",
            "title": "Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                },
                {
                    "id": 4940,
                    "therapyName": "Enzalutamide + Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02957968",
            "title": "Neoadj Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1495,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 5729,
                    "therapyName": "Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02983604",
            "title": "GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 738,
                    "therapyName": "Exemestane",
                    "synonyms": null
                },
                {
                    "id": 5074,
                    "therapyName": "Fulvestrant + GS-5829",
                    "synonyms": null
                },
                {
                    "id": 3561,
                    "therapyName": "Exemestane + GS-5829",
                    "synonyms": null
                },
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03007979",
            "title": "Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 759,
                    "therapyName": "Goserelin",
                    "synonyms": null
                },
                {
                    "id": 3205,
                    "therapyName": "Fulvestrant + Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 2922,
                    "therapyName": "Letrozole + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03018080",
            "title": "Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer (PePPy)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4021,
                    "therapyName": "Paclitaxel + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03044730",
            "title": "Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4022,
                    "therapyName": "Capecitabine + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03051659",
            "title": "A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 728,
                    "therapyName": "Eribulin",
                    "synonyms": null
                },
                {
                    "id": 3080,
                    "therapyName": "Eribulin + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03051672",
            "title": "Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03056755",
            "title": "Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5929,
                    "therapyName": "Alpelisib + Fulvestrant",
                    "synonyms": null
                },
                {
                    "id": 1553,
                    "therapyName": "Alpelisib + Letrozole",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03070002",
            "title": "Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1198,
                    "therapyName": "Denosumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03078751",
            "title": "Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer (EarLEE-1)",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 790,
                    "therapyName": "Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03092934",
            "title": "A Study of AK-01 (LY3295668) in Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5753,
                    "therapyName": "LY3295668",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03128619",
            "title": "Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 5594,
                    "therapyName": "Copanlisib + Letrozole + Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 5593,
                    "therapyName": "Copanlisib + Letrozole",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03132467",
            "title": "Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 Antibody (Tremelimumab) in HR+/HER2- Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03147287",
            "title": "Palbociclib After CDK and Endocrine Therapy (PACE)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 3205,
                    "therapyName": "Fulvestrant + Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 5684,
                    "therapyName": "Avelumab + Fulvestrant + Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03166085",
            "title": "PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5796,
                    "therapyName": "Nab-paclitaxel + PU-H71",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03225547",
            "title": "Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6030,
                    "therapyName": "Mifepristone + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03241810",
            "title": "Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer (SHERBOC)",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                },
                {
                    "id": 6327,
                    "therapyName": "Fulvestrant + Seribantumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03280563",
            "title": "A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6269,
                    "therapyName": "Atezolizumab + Ipatasertib",
                    "synonyms": null
                },
                {
                    "id": 6270,
                    "therapyName": "Atezolizumab + Bevacizumab + Exemestane",
                    "synonyms": null
                },
                {
                    "id": 1343,
                    "therapyName": "Atezolizumab + Cobimetinib",
                    "synonyms": null
                },
                {
                    "id": 6271,
                    "therapyName": "Atezolizumab + Bevacizumab + Fulvestrant",
                    "synonyms": null
                },
                {
                    "id": 6272,
                    "therapyName": "Atezolizumab + Bevacizumab + Tamoxifen",
                    "synonyms": null
                },
                {
                    "id": 6273,
                    "therapyName": "Atezolizumab + Fulvestrant + Ipatasertib",
                    "synonyms": null
                },
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                },
                {
                    "id": 6268,
                    "therapyName": "Atezolizumab + Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03285412",
            "title": "CDK 4/6 Inhibitor, LEE011 (Ribociclib), in Combination With Adjuvant Endocrine Therapy at Varying Duration for ER-positive Breast Cancer",
            "phase": null,
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 790,
                    "therapyName": "Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03285607",
            "title": "MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 6236,
                    "therapyName": "Cyclophosphamide + Doxorubicin + MCS110 + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03286842",
            "title": "To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03294694",
            "title": "Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6285,
                    "therapyName": "Fulvestrant + Ribociclib + Spartalizumab",
                    "synonyms": null
                },
                {
                    "id": 6284,
                    "therapyName": "Ribociclib + Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03326674",
            "title": "Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC (CONTESSA)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1105,
                    "therapyName": "Capecitabine",
                    "synonyms": null
                },
                {
                    "id": 8389,
                    "therapyName": "Capecitabine + Tesetaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03329937",
            "title": "Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 832,
                    "therapyName": "Niraparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03332797",
            "title": "A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6445,
                    "therapyName": "GDC-9545 + Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 6444,
                    "therapyName": "GDC-9545",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03337724",
            "title": "A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (IPATunity130)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1588,
                    "therapyName": "Ipatasertib + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03344536",
            "title": "A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer",
            "phase": null,
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6478,
                    "therapyName": "Debio 1347 + Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03363893",
            "title": "Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6828,
                    "therapyName": "ICEC0942",
                    "synonyms": null
                },
                {
                    "id": 8454,
                    "therapyName": "Fulvestrant + ICEC0942",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03393845",
            "title": "Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6580,
                    "therapyName": "Fulvestrant + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03430518",
            "title": "Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6689,
                    "therapyName": "Durvalumab + Eribulin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03439735",
            "title": "Determinants of Resistance to First-line Therapy With an AI and Palbociclib for HR+ MBC",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03455270",
            "title": "G1T48, an Oral SERD, in ER-Positive, HER2-Negative Advanced Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6206,
                    "therapyName": "G1T48",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03471663",
            "title": "A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6826,
                    "therapyName": "D-0502 + Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 6825,
                    "therapyName": "D-0502",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03473639",
            "title": "A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy (Breast 49)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7360,
                    "therapyName": "Capecitabine + Entinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03477396",
            "title": "Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 790,
                    "therapyName": "Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03519178",
            "title": "A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 as a Single Agent and in Combination With Endocrine Therapy",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6969,
                    "therapyName": "PF-06873600",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03524170",
            "title": "RACHEL1: Radiation and CHEckpoint bLockade Trial in Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5860,
                    "therapyName": "M7824",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03554044",
            "title": "Talimogene Laherparepvec With Paclitaxel or Endocrine Therapy in Treating Participants With Metastatic, Unresectable, or Recurrent HER2- Negative Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7119,
                    "therapyName": "Letrozole + Talimogene laherparepvec",
                    "synonyms": null
                },
                {
                    "id": 7120,
                    "therapyName": "Talimogene laherparepvec + Tamoxifen",
                    "synonyms": null
                },
                {
                    "id": 7117,
                    "therapyName": "Exemestane + Talimogene laherparepvec",
                    "synonyms": null
                },
                {
                    "id": 7118,
                    "therapyName": "Fulvestrant + Talimogene laherparepvec",
                    "synonyms": null
                },
                {
                    "id": 7115,
                    "therapyName": "Anastrozole + Talimogene laherparepvec",
                    "synonyms": null
                },
                {
                    "id": 7114,
                    "therapyName": "Paclitaxel + Talimogene laherparepvec",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03560531",
            "title": "A Study of ZN-c5 in Subjects With Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7056,
                    "therapyName": "Palbociclib + ZN-c5",
                    "synonyms": null
                },
                {
                    "id": 7055,
                    "therapyName": "ZN-c5",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03566485",
            "title": "Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7150,
                    "therapyName": "Atezolizumab + Idasanutlin",
                    "synonyms": null
                },
                {
                    "id": 1343,
                    "therapyName": "Atezolizumab + Cobimetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03568422",
            "title": "CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7713,
                    "therapyName": "CFI-402257 + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03613220",
            "title": "CompLEEment-1 Canadian Correlative Sub-Study (LEEomic)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1568,
                    "therapyName": "Letrozole + Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03624543",
            "title": "CFI-400945 in Patients With Advanced/Metastatic Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4029,
                    "therapyName": "CFI-400945",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03628066",
            "title": "Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7716,
                    "therapyName": "Goserelin + Letrozole + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03633331",
            "title": "Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7339,
                    "therapyName": "Fulvestrant + Letrozole + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03650894",
            "title": "Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7405,
                    "therapyName": "Bicalutamide + Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03659136",
            "title": "The XENERA-1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Post-menopausal Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7689,
                    "therapyName": "Everolimus + Exemestane + Xentuzumab",
                    "synonyms": null
                },
                {
                    "id": 1966,
                    "therapyName": "Everolimus + Exemestane",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03685331",
            "title": "Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 7528,
                    "therapyName": "Fulvestrant + Olaparib + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03685591",
            "title": "PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7496,
                    "therapyName": "PF-06952229",
                    "synonyms": null
                },
                {
                    "id": 7498,
                    "therapyName": "Enzalutamide + PF-06952229",
                    "synonyms": null
                },
                {
                    "id": 7497,
                    "therapyName": "Letrozole + Palbociclib + PF-06952229",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03701334",
            "title": "A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 790,
                    "therapyName": "Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03725436",
            "title": "ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7559,
                    "therapyName": "ALRN-6924 + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03774472",
            "title": "Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Participants With Estrogen Receptor Positive, HER2 Negative Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7619,
                    "therapyName": "Hydroxychloroquine + Letrozole + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03781063",
            "title": "Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7675,
                    "therapyName": "Lasofoxifene",
                    "synonyms": null
                },
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03789110",
            "title": "NIMBUS: A Phase II Study of Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03804944",
            "title": "Converting HR+ Breast Cancer Into an Individualized Vaccine (CBCV)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3007,
                    "therapyName": "CDX-301",
                    "synonyms": null
                },
                {
                    "id": 7724,
                    "therapyName": "CDX-301 + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03822468",
            "title": "Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (PMR)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5310,
                    "therapyName": "Goserelin + Letrozole + Ribociclib",
                    "synonyms": null
                },
                {
                    "id": 7166,
                    "therapyName": "Anastrozole + Ribociclib",
                    "synonyms": null
                },
                {
                    "id": 8456,
                    "therapyName": "Anastrozole + Goserelin + Ribociclib",
                    "synonyms": null
                },
                {
                    "id": 1568,
                    "therapyName": "Letrozole + Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03840200",
            "title": "A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7867,
                    "therapyName": "Ipatasertib + Rucaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03854903",
            "title": "WI231696: ASPIRE Bosutinib",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7965,
                    "therapyName": "Bosutinib + Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 7966,
                    "therapyName": "Bosutinib + Fulvestrant + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03858972",
            "title": "Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC (CONTESSA 2)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8389,
                    "therapyName": "Capecitabine + Tesetaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03901339",
            "title": "Study of IMMU-132 in HR+/HER2- MBC (TROPICS-02)",
            "phase": "Phase III",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 728,
                    "therapyName": "Eribulin",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 1685,
                    "therapyName": "Vinorelbine",
                    "synonyms": null
                },
                {
                    "id": 1105,
                    "therapyName": "Capecitabine",
                    "synonyms": null
                },
                {
                    "id": 3227,
                    "therapyName": "Sacituzumab govitecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03911973",
            "title": "Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8159,
                    "therapyName": "Gedatolisib + Talazoparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03939897",
            "title": "Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer - Dose-Finding Study",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5859,
                    "therapyName": "Abemaciclib + Fulvestrant",
                    "synonyms": null
                },
                {
                    "id": 9420,
                    "therapyName": "Abemaciclib + Copanlisib + Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03950570",
            "title": "ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9707,
                    "therapyName": "ORIN1001 + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 9657,
                    "therapyName": "ORIN1001",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03955939",
            "title": "A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8391,
                    "therapyName": "LY3295668 + Midazolam",
                    "synonyms": null
                },
                {
                    "id": 5753,
                    "therapyName": "LY3295668",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03959891",
            "title": "AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8394,
                    "therapyName": "Fulvestrant + Ipatasertib + Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 747,
                    "therapyName": "Ipatasertib",
                    "synonyms": null
                },
                {
                    "id": 8393,
                    "therapyName": "Fulvestrant + Ipatasertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03988114",
            "title": "A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer (proMONARCH)",
            "phase": "FDA approved",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 2255,
                    "therapyName": "Abemaciclib + Anastrozole",
                    "synonyms": null
                },
                {
                    "id": 2254,
                    "therapyName": "Abemaciclib + Letrozole",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03990896",
            "title": "Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 682,
                    "therapyName": "Talazoparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04024436",
            "title": "A Study of TAS-120 in Patients With Metastatic Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8602,
                    "therapyName": "Fulvestrant + Futibatinib",
                    "synonyms": null
                },
                {
                    "id": 1053,
                    "therapyName": "Futibatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04031885",
            "title": "A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer",
            "phase": "FDA approved",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5859,
                    "therapyName": "Abemaciclib + Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04038489",
            "title": "COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer (Breast 51)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 8640,
                    "therapyName": "Aspirin + Cyclophosphamide + Doxorubicin + Paclitaxel + Tamoxifen",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04042480",
            "title": "A Study of SGN-CD228A in Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9761,
                    "therapyName": "SGN-CD228A",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04052555",
            "title": "Testing the Addition of an Anti-cancer Drug, M6620, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative or Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2879,
                    "therapyName": "VX-970",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04059484",
            "title": "Phase 2 Study of SAR439859 Versus Physician's Choice in Premenopausal and Postmenopausal Locally Advanced or Metastatic ER-positive Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6293,
                    "therapyName": "SAR439859",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04060862",
            "title": "A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer (IPATunity150)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8394,
                    "therapyName": "Fulvestrant + Ipatasertib + Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 3205,
                    "therapyName": "Fulvestrant + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04064359",
            "title": "Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors and HER2-neg Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8717,
                    "therapyName": "MEN1309",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04072952",
            "title": "Clinical Trial of ARV-471 in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (mBC)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8716,
                    "therapyName": "ARV-471",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04075604",
            "title": "A Study of Neoadjuvant Nivolumab + Abemaciclib or Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer (CheckMate 7A8)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2255,
                    "therapyName": "Abemaciclib + Anastrozole",
                    "synonyms": null
                },
                {
                    "id": 4974,
                    "therapyName": "Anastrozole + Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 8715,
                    "therapyName": "Anastrozole + Nivolumab + Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 8714,
                    "therapyName": "Abemaciclib + Anastrozole + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04088032",
            "title": "Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 8725,
                    "therapyName": "Abemaciclib + Durvalumab + Exemestane",
                    "synonyms": null
                },
                {
                    "id": 8726,
                    "therapyName": "Abemaciclib + Anastrozole + Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 8727,
                    "therapyName": "Abemaciclib + Durvalumab + Letrozole",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04090567",
            "title": "Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1971,
                    "therapyName": "Cediranib + Olaparib",
                    "synonyms": null
                },
                {
                    "id": 4739,
                    "therapyName": "AZD6738 + Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04095273",
            "title": "Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8754,
                    "therapyName": "BAY1895344 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04132817",
            "title": "A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2-Breast Cancer That Has Spread",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 2489,
                    "therapyName": "Nab-paclitaxel + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 8869,
                    "therapyName": "Ipilimumab + Nab-paclitaxel + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04174352",
            "title": "FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 1456,
                    "therapyName": "Tamoxifen",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04182516",
            "title": "Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9564,
                    "therapyName": "NMS-03305293",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04185311",
            "title": "Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9035,
                    "therapyName": "Ipilimumab + Nivolumab + Talimogene laherparepvec",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04188548",
            "title": "A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9042,
                    "therapyName": "Abemaciclib + LY3484356",
                    "synonyms": null
                },
                {
                    "id": 9041,
                    "therapyName": "LY3484356",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04191382",
            "title": "Study of SAR439859 Versus Letrozole in ER Positive, HER2 Negative Pre-operative Post-menopausal Primary Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 794,
                    "therapyName": "Letrozole",
                    "synonyms": null
                },
                {
                    "id": 6293,
                    "therapyName": "SAR439859",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04214288",
            "title": "A Comparative Study of AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer (SERENA-2)",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 7531,
                    "therapyName": "AZD9833",
                    "synonyms": null
                },
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04220476",
            "title": "CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer (CIMER)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2922,
                    "therapyName": "Letrozole + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04225117",
            "title": "A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4125,
                    "therapyName": "Enfortumab vedotin-ejfv",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04274933",
            "title": "A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9402,
                    "therapyName": "Capecitabine + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04288089",
            "title": "A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9521,
                    "therapyName": "H3B-6545 + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04305236",
            "title": "Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 5859,
                    "therapyName": "Abemaciclib + Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04305496",
            "title": "Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer (CAPItello-291)",
            "phase": "Phase III",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 4452,
                    "therapyName": "Capivasertib + Fulvestrant",
                    "synonyms": null
                },
                {
                    "id": 744,
                    "therapyName": "Fulvestrant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04305834",
            "title": "Abemaciclib Monotherapy in Treating Older Patients With Hormone Receptor Positive Metastatic Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 802,
                    "therapyName": "Abemaciclib",
                    "synonyms": null
                }
            ]
        }
    ]
}